On November 10, 2020 ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, reported that Chris Martin, Chief Executive Officer, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 am ET (Press release, ADC Therapeutics, NOV 10, 2020, View Source [SID1234570436]). A live webcast of the presentation will be available at View Source An archived version of the webcast will be available after the completion of the event at www.ir.adctherapeutics.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!